Evaluating Weight Loss Outcomes in Patients With Overweight or Obesity

April 20, 2026 updated by: Huda Omran, Aldafter Medical Center, Bahrain
The goal of this observational study is to evaluate weight loss outcomes in adults with overweight or obesity using weight management medications. The main questions it aims to answer are: (1) How much weight do patients lose after 12 months? (2) Do blood sugar and cholesterol levels improve? (3) How safe and tolerable are these medications? This is a retrospective study using existing medical records and pharmacy claims. Participants will not be asked to do anything new; all data will be collected from routine clinical care.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

The goal of this observational study is to learn how much weight adults with overweight or obesity lose after taking weight management for 12 months. The study also aims to learn whether these medications improve blood sugar and cholesterol levels, and how safe and tolerable they are.

The main questions it aims to answer are:

How much weight (in kilograms and percentage) do patients lose after 12 months of treatment? Do patients' fasting blood sugar, HbA1c, and cholesterol levels improve after 12 months? What side effects or treatment discontinuations occur in routine clinical practice? Researchers will compare weight loss outcomes among different patient groups based on age, sex, baseline BMI, and the specific medication used.

This is a retrospective study, meaning participants will not be asked to do anything new. Researchers will collect information from existing medical records and pharmacy claims at Aldafter Medical Center (ADMC) in Bahrain, including weight measurements, lab results, and medication histories from routine clinical care.

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Bahrain
      • Manama, Bahrain
        • AlDafter Medical center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients (≥18 years) with overweight or obesity (BMI ≥25) who received weight management medications. Patients must have continuous insurance enrollment for 12 months before and after treatment initiation, and weight measurements at both baseline and 12 months.

Description

Inclusion Criteria:

  1. Age: Adults aged 18 years or older.
  2. Body Mass Index (BMI): Patients classified as overweight (BMI 25-29.9 kg/m²) or obese (BMI ≥30 kg/m²).
  3. Medication: At least one pharmacy claim for any approved weight management medication

  4. Continuous Enrollment: Patients must have continuous enrollment in medical and pharmacy insurance for 1 year prior to the index date (date of treatment initiation) and 1 year afterward.

    -

Exclusion Criteria:

  1. Type 1 Diabetes: Patients with a diagnosis of type 1 diabetes.
  2. Non-Compliance: Evidence of non-compliance with treatment (e.g., gaps in therapy greater than 30 days).
  3. Bariatric Surgery: Patients who have undergone bariatric surgery in the past 5 years.
  4. Serious Comorbidities: Presence of serious medical conditions that may confound weight loss outcomes (e.g., uncontrolled psychiatric disorders, cancer).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Absolute Weight Change
Time Frame: Baseline to 12 months
Absolute weight change (kg) from baseline to 12 months
Baseline to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Aldafter Medical Center, Bahrain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 25, 2025

Primary Completion (Estimated)

June 25, 2026

Study Completion (Estimated)

October 30, 2026

Study Registration Dates

First Submitted

April 20, 2026

First Submitted That Met QC Criteria

April 20, 2026

First Posted (Actual)

April 24, 2026

Study Record Updates

Last Update Posted (Actual)

April 24, 2026

Last Update Submitted That Met QC Criteria

April 20, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ADMC-WL-2025-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared with other researchers. Only de-identified aggregate results will be published.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight and Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe